verapamil has been researched along with Epilepsies, Myoclonic in 3 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Epilepsies, Myoclonic: A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil was co-administered in both children with a prompt response in controlling status epilepticus, myoclonic jerks, and partial and generalized seizures." | 1.35 | Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. ( Iannetti, P; Parisi, P; Ruggieri, M; Spalice, A; Zara, F, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brigo, F | 1 |
| Striano, P | 2 |
| Balagura, G | 1 |
| Belcastro, V | 1 |
| Iannetti, P | 1 |
| Parisi, P | 1 |
| Spalice, A | 1 |
| Ruggieri, M | 1 |
| Zara, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
1 review available for verapamil and Epilepsies, Myoclonic
| Article | Year |
|---|---|
Emerging drugs for the treatment of Dravet syndrome.
Topics: Animals; Cannabidiol; Epilepsies, Myoclonic; Fenfluramine; Humans; Serotonin Agents; Verapamil | 2018 |
2 other studies available for verapamil and Epilepsies, Myoclonic
| Article | Year |
|---|---|
Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy.
Topics: Adolescent; Anticonvulsants; Calcium Channel Blockers; Child, Preschool; Chromosomes, Human, Pair 2; | 2009 |
Comment to: addition of verapamil in the treatment of severe myoclonic epilepsy in infancy (Iannetti et al.).
Topics: Anticonvulsants; Calcium Channel Blockers; Epilepsies, Myoclonic; Humans; Infant; Verapamil | 2009 |